Prolactin, or luteotropic hormone, is a single polypeptide chain that is best known to initiate and sustain lactation, maintain the corpus luteum, and stimulate growth and differentiation of breast tissue. A versatile and potent molecule, it is known to have more than 300 functions in the body. Prolactin is structurally similar to growth hormone and is involved in mediating communication among the endocrine, nervous, and immune systems. Furthermore, recent evidence demonstrates a tumorigenic role for prolactin in breast, prostate, endometrial, ovarian, and liver cancers.

Prolactin is produced chiefly by cells called lactotrophs in the anterior pituitary gland, under the control of dopamine, which is secreted from the hypothalamus and inhibits prolactin synthesis and release. Outside the pituitary, however, prolactin is known to be produced by other cell and tissue types, such as uterine endometrium (decidua), glandular and adipose breast tissue, T cell lymphocytes, the prostate, and the hypothalamus.

Elevated levels of prolactin in circulation, called hyperprolactinemia, is relatively common and may be caused by a vast number of physiologic and pathologic conditions. In women, hyperprolactinemia may result in irregular ovulation, menstrual abnormalities (amenorrhea or oligomenorrhea), or milk production in non-pregnant individuals (galactorrhea). In males, elevated prolactin levels are linked to impotence, diminished libido, infertility, and galactorrhea. While these conditions are relatively benign, prolactin has long been implicated in the spread of cancer, dating back to the 1960s and 1970s. Over approximately the last two decades, studies of prolactin-mediated signaling pathways and extra-pituitary prolactin expression have illuminated the role this powerful molecule plays in cancer progression.

Prolactin Signaling Pathways

The prolactin signaling pathways studied most often are those involving Janus Kinase-2 (Jak2) and Signal Transducer and Activator of Transcription-5 (Stat5), Ras and Mitogen Activated Protein Kinase (MAPK), and Phosphatidylinositol 3-Kinase (PI3K) and Akt kinase. These pathways are also stimulated by growth hormone and control essential cellular processes like differentiation, proliferation, survival, and motility. (Figure 1.)

The Jak2-Stat5 cascade is one of the major signaling pathways stimulated by cytokines and growth factors. Its activation affects cell proliferation, differentiation, migration, and apoptosis. In breast tissue, prolactin-mediated stimulation of the Jak2-Stat5 pathway controls the majority of physiological functions in the mammary gland, such as the induction of gene transcription for proliferation/cell cycle and milk proteins.

The Ras-MAPK signaling pathway regulates many key cellular functions, such as growth, proliferation, and apoptosis. Mutations associated with this pathway are directly linked to several types of cancer. Even in the absence of genetic aberrations, this pathway is activated in more than 50% of acute myelogenous leukemia, acute lymphocytic leukemia, and other malignancies. Activation of the PI3K-Akt pathway

Human Prolactin

For more than 30 years, Scripps has been a leading manufacturer of the highest quality proteins and immunoreagents. Produced on-site in San Diego, Scripps offers both native and recombinant prolactin. Our products are reliable and are provided with consistent quality and on-time delivery.

<table>
<thead>
<tr>
<th>Cat. #</th>
<th>Description</th>
<th>Purity</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0414</td>
<td>Native Human Prolactin</td>
<td>≥50%</td>
</tr>
<tr>
<td>P0415</td>
<td>Native Human Prolactin</td>
<td>≥95%</td>
</tr>
<tr>
<td>P1516</td>
<td>Recomb. Human Prolactin</td>
<td>≥95%</td>
</tr>
</tbody>
</table>

Prolactin Monoclonal and Polyclonal antibodies are also available.

Contact us today for pricing or more information:
(+1) 858.546.5800 contact@scrippslabs.com
results in cell survival and proliferation, by modulating cell cycle regulatory proteins, and also impacts cellular migration, differentiation, and adhesion. Dysfunction of this pathway is known as a causative factor in carcinogenesis. In addition, germ line mutations that affect this pathway are noted in several genetically linked forms of cancer.5,22,23

Epidemiological Studies
Prolactin’s role in tumorigenesis has been studied for quite some time in breast cancer, dating back to 1962 when Boot et al. demonstrated that high circulating levels of prolactin promoted mammary tumor growth in mouse models.13 Numerous additional studies were performed in the 1980s and 1990s, but only modest or no correlations were noted between high circulating prolactin levels and breast cancer risk.19,24 A retrospective evaluation, however, revealed that these studies were limited by a number of factors, such as small study populations, availability of post-diagnosis samples only, and only one sample being drawn from each study participant, which prevented prolactin levels from being monitored over a period of time.24,25

In a review of data obtained from the Nurses’ Health Studies (NHS) 1 and 2, which involved more than 237,000 female subjects, a link between prolactin and breast cancer risk was established.24 A retrospective evaluation, however, revealed that these studies were limited by a number of factors, such as small study populations, availability of post-diagnosis samples only, and only one sample being drawn from each study participant, which prevented prolactin levels from being monitored over a period of time.24,25

A retrospective study of data obtained from the Nurses’ Health Studies (NHS) 1 and 2, which involved more than 237,000 female subjects, a link between prolactin and breast cancer risk was established.24 A retrospective evaluation, however, revealed that these studies were limited by a number of factors, such as small study populations, availability of post-diagnosis samples only, and only one sample being drawn from each study participant, which prevented prolactin levels from being monitored over a period of time.24,25

A retrospective study of data obtained from the Nurses’ Health Studies (NHS) 1 and 2, which involved more than 237,000 female subjects, a link between prolactin and breast cancer risk was established.24 A retrospective evaluation, however, revealed that these studies were limited by a number of factors, such as small study populations, availability of post-diagnosis samples only, and only one sample being drawn from each study participant, which prevented prolactin levels from being monitored over a period of time.24,25

Table 2: Possible Pathologic Causes of Hyperprolactinemia

<table>
<thead>
<tr>
<th>Pituitary Disorders</th>
<th>CNS Disorders</th>
<th>Other Disease States</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolactinomas</td>
<td>Tumors</td>
<td>Severe Hypothyroidism</td>
</tr>
<tr>
<td>Mixed Pituitary Adenomas</td>
<td>Granulomatous Diseases</td>
<td>Epatic Cirrhosis</td>
</tr>
<tr>
<td>Cushing’s Disease</td>
<td>Vascular Disorders</td>
<td>Chronic Renal Failure</td>
</tr>
<tr>
<td>Acromegaly</td>
<td>Autoimmune Disorders</td>
<td>Polycystic Ovary Syndrome</td>
</tr>
<tr>
<td>Non-Secreting Adenomas</td>
<td>Hypothalamic Tumors</td>
<td>Estrogen-Secreting Tumors</td>
</tr>
<tr>
<td>Empty Sella Syndrome</td>
<td>Cranial Irradiation</td>
<td>Pseudocyesis</td>
</tr>
<tr>
<td>Pituitary Stalk Tumors</td>
<td>Seizures</td>
<td>Chest Wall Trauma</td>
</tr>
<tr>
<td>Lymphoid Hypophysitis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Breast Cancer</td>
</tr>
<tr>
<td></td>
<td>Liver Cancer</td>
</tr>
<tr>
<td></td>
<td>Ovarian Cancer</td>
</tr>
<tr>
<td></td>
<td>Prostate Cancer</td>
</tr>
</tbody>
</table>

Many studies demonstrate that prolactin, whether produced locally or by the pituitary, promotes tumor growth in mammary tissue by activation of the Jak2-Stat5 and Ras-MAPK pathways.5,19,20,21,22,23,24,25,26,27 In a 2013 study, Barcus et al. evaluated the roles of prolactin signaling and ECM density in breast cancer invasiveness.28 The authors found that in stiff, dense collagen matrices, prolactin activated ERK1/2, a component of the Ras-MAPK pathway, and increased the expression of matrix metalloproteinase-2 (MMP-2). Both consequences of prolactin signaling increased the invasive behavior of breast cancer cells.

The PI3K-Akt pathway, although not yet directly linked to cancer by way of prolactin, does produce several downstream metabolites that regulate systems important in oncogenesis, such as proliferation, inhibition of apoptosis, angiogenesis, and cytoskeletal rearrangements.29,30,31,32,33,34,35 By affecting these downstream processes, prolactin may have an indirect role in tumor progression. Further study is warranted.

In addition to mammary carcinoma, prolactin mediation of the Jak2-Stat5 pathway is also implicated in the development of prostate cancer. Both prolactin and its receptor are expressed in normal and malignant prostate epithelium, suggesting the possibility of an autocrine prolactin signaling mechanism.36,37 In two separate studies, Li et al. demonstrated that Stat5 activation is associated with a higher tumor grade and earlier recurrence in prostate cancer.44,45 In a follow-up study, Dagvadorj et al. clearly demonstrated that autocrine prolactin, independent from pituitary prolactin, promotes prostate cancer cell growth by activation of the Jak2-Stat5 pathway.46

Prolactin in Other Malignancies
Evidence is mounting for a role of prolactin in at least two gynecologic malignancies: Endometrial and ovarian cancer. An exhaustive 2007 study evaluated the ability of 64 biomarkers to distinguish endometrial cancer from breast and ovarian cancers. Among all the markers, prolactin was best able to identify patients with endometrial cancer, and by quite a large margin: The prolactin assay demonstrated 98.3% sensitivity and

SCRIPPS LABORATORIES, INC.  6838 Flanders Drive, San Diego, CA 92121  •  Tel: (+1) 858.546.5800  contact@scrippslabs.com
In ovarian cancer, serum levels of prolactin do not strongly correlate with risk of disease development in the general population, but elevated levels are associated with increased risk in two population subsets: overweight women and those with a strong family history of ovarian cancer.\textsuperscript{48,49} Furthermore, factors associated with a reduced risk of ovarian cancer, such as having borne children and the use of oral contraceptives, correlate strongly with lower prolactin levels, suggesting a role for prolactin in mediating these effects.\textsuperscript{48} Additional study is needed.

Experimental evidence suggests a causative role for prolactin in endometrial and ovarian tumorigenesis, although not as much data exists as does for breast and prostate cancers. Levin\textit{a}\textit{et al.} found the presence of prolactin mRNA and over-expression of the prolactin receptor in ovarian and endometrial tumors.\textsuperscript{49} The authors also demonstrated prolactin’s ability to induce proliferation in endometrial and ovarian cancer cell lines. In addition, they found that prolactin was able to transform normal ovarian epithelial cells into cancerous tissue by way of Ras activation, a factor implicated in endometrial and ovarian carcinogenesis.\textsuperscript{50,51,52} More study is needed, but the involvement of prolactin in these malignancies appears likely.

Prolactin may also be involved in liver cancer, as a recent study reported significantly elevated serum prolactin levels in patients with hepatocellular carcinoma, compared to healthy controls.\textsuperscript{53} The study also evaluated prolactin receptor expression and Jak2 activation in patient tissue samples, and both were found to correlate with a poor outcome. Further analysis confirmed that prolactin induced the activation of Jak2 and cyclin D1 in hepatocellular carcinoma cells, suggesting the proliferation of liver cancer may occur by way of the Jak2-Stat5 signaling pathway.

Since then, prolactin has been shown to predict treatment failure, disease recurrence, and a lower overall survival rate in breast cancer. In addition, its expression in tissue indicates tumorigenic potential and increased risk of developing disease in breast, prostate, endometrial, ovarian, and liver cancers. With prolactin’s seemingly ubiquitous synthesis and secretion, along with its involvement in multiple intracellular signaling pathways, it’s likely that even more roles and functions will be revealed in the near future.

References


---

Figure 1: Key prolactin-mediated signaling pathways

---
### Human Hormones

Scripps Laboratories is one of the world’s leading primary manufacturers of human hormones, with quality unmatched in the industry. High purity, partially pure, alpha and beta subunits, and whole molecule preparations are available.

Use the links below to learn more about these high quality products.

**Contact us today for pricing or more information:**

(+1) 858.546.5800  contact@scrippslabs.com

---

**Prolactin, Cancer Risk & Tumorigenesis - continued**


---

**Abbr. | Description | Purity Levels**
---
**hCG** | Chorionic Gonadotropin | ≥15%, ≥80%, ≥99%
**α-hCG, β-hCG** | Chorionic Gonadotropin Subunits | ≥98%
**hFSH** | Follicle Stimulating Hormone | ≥20%, ≥75%, ≥95%
**α-hFSH, β-hFSH** | Follicle Stimulating Hormone Subunits | ≥98%
**hGH** | Growth Hormone | ≥70%, ≥98%
**hLH** | Luteinizing Hormone | ≥50%, ≥95%, ≥98%
**α-hLH, β-hLH** | Luteinizing Hormone Subunits | ≥98%
**hPL** | Placental Lactogen | ≥95%
**hPRL** | Prolactin - Native & Recombinant | ≥50%, ≥95%
**hTSH** | Thyroid Stimulating Hormone | ≥20%, ≥90%, ≥95%
**α-hTSH, β-hTSH** | Thyroid Stimulating Hormone Subunits | ≥98%

*Selected monoclonal & polyclonal antibodies are also available.*

---

Author contact information: dgeorge@scrippslabs.com